Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and…
Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST PARIS and CAMBRIDGE, Mass., April17, 2024(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial and operational results for the fourth quarter and full year ended December...
Nasdaq GlobeNewswire
17/04/2024
Ipsen publishes its 2023 Universal Registration Document
Ipsen publishes its2023 Universal Registration DocumentPARIS, FRANCE, 17 April 2024 -Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty biopharmaceutical group, announces that its 2023 Universal Registration Document has been filed with the FrenchAutorité des Marchés Financierson 17 April 2024 and registered under the number D.24-0288.The document is available onipsen.comandamf-france.org. Copies will also be available at Ipsen's headquarters – 65 quai...
Nasdaq GlobeNewswire
17/04/2024
Derm-Biome Pharmaceuticals' topical therapy shows positive…
Derm-Biome Pharmaceuticals is a Vancouver-based biopharmaceutical company that has developed a topical anticancer treatment for patients with or at high risk of developing multiple AKs. In a recent UV-induced skin cancer trial, mice were exposed to UVB radiation over a period of 25 weeks. The prolonged exposure mimics chronic sun exposure over time and replicates the gradual progression from precancerous skin conditions to cutaneous squamous cell carcinoma (cSCC). Topical application of...
Nasdaq GlobeNewswire
17/04/2024
Patient Monitoring Devices Market Worth $71.1 billion | MarketsandMarkets™
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=678 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=678 Browse in-depth TOC on "Patient Monitoring Devices Market" 215 - Tables 55 - Figures 250 - Pages Patient Monitoring Devices Market Scope: Blood Glucose Monitoring systems segment to register a significant growth rate over the forecast period of 2024-2029. Based on the...
PR Newswire
17/04/2024
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing…
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for one-year clinical efficacy readout in Q3 2024COPENHAGEN, Denmark, April17, 2024(GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces that the first patient in its EVX-01 Phase 2 trial in...
Nasdaq GlobeNewswire
17/04/2024
PeploBio and IncellDX Partner to Launch the First Long COVID Test in the UK and…
"Our collaboration with PeploBio marks a pivotal moment in the battle against Long COVID. The incellKINE Long Hauler Index technology enables us to identify a distinctive immunologic profile unique to Long COVID patients, providing a crucial first step for personalised treatment strategies," said Bruce Patterson, M.D., Founder and CEO at IncellDX. "Our collaboration with PeploBio marks a pivotal moment in the battle against Long COVID. The incellKINE Long Hauler Index technology…
PR Newswire
17/04/2024
135th Canton Fair Showcases Innovations: A Stage for Cutting-Edge Tech Products
At the forefront of modern technological conveniences is the challenge of reducing operational noise to enhance quality of life—a concern shared by both consumers and businesses. GZ Dotels Electric Appliances Co., Ltd., a company with years of expertise in cooling and heating as well as new energy technologies, leads the industry with its advancements in silent technology, product efficiency, and corrosion-resistant materials. Among its showcased products are the R290 Integrated Air Source Heat…
PR Newswire
17/04/2024
Goalkeeping Legend Manuel Neuer Signs as Hisense UEFA EURO 2024™ Brand…
Just as goalkeepers like Manuel stand as the last line of defense, Hisense serves as the reliable force behind the scenes, consistently delivering cutting-edge technology and unparalleled quality. Just as goalkeepers like Manuel stand as the last line of defense, Hisense serves as the reliable force behind the scenes, consistently delivering cutting-edge technology and unparalleled quality. Five-time International Federation of Football History & Statistics (IFFHS) 'World's Best...
PR Newswire
17/04/2024
Clarivate Launches LatAm Market Tracking Solution in Partnership with Global…
The new solution is the next phase of an expanding partnership between Clarivate and Global Healthcare Intelligence, enabling in-depth and actionable analysis of the medical device market in Latin America (LatAm). Leveraging comprehensive datasets and the proprietary Clarivate device catalog for the LatAm region, including Brazil, Colombia, Argentina, Chile, Peru, and Ecuador, clients can analyze over 100 medical devices and 500 product categories. The new solution is the next phase of an...
PR Newswire
17/04/2024
Xeltis Announces Latest Results from aXess Trials to be Presented at 46th Annual…
Dr Shahverdyan will be unveiling the latest results from the aXess trials, multicentric European single arm studies evaluating the safety and performance of the aXess graft in subjects older than 18 years with end-stage renal disease and deemed unsuitable for fistula creation. Dr Shahverdyan will be unveiling the latest results from the aXess trials, multicentric European single arm studies evaluating the safety and performance of the aXess graft in subjects older than 18 years with end-stage...
PR Newswire
17/04/2024
World Hemophilia Day 2024"Equitable access for all: recognizing all bleeding…
There are many ways you can bring attention to hemophilia and other inherited bleeding disorders in your local and global community to raise awareness of the need for inclusion in national policy. Whether you are a person with a bleeding disorder, a national member organization (NMO), or a healthcare professional, here are just a few things you can do to get started: There are many ways you can bring attention to hemophilia and other inherited bleeding disorders in your local and global...
PR Newswire
17/04/2024
Essity joins United Nations initiative to promote inclusive advertising
Essity and its brands have a long history of breaking taboos, raise awareness against bias and act for equality. For example through campaigns by its feminine care brands Bodyform/Libresse/Nosotras/Saba, and the global market leading incontinence care brand TENA, such as 'Blood Normal', which was the first TV advertisement for period products to replace blue liquid with a more representative red, 'Viva La Vulva' and 'Befriend your Body', which help normalize the conversation about the female…
PR Newswire
17/04/2024
Orexo extends patent protection for its nasal epinephrine powder product OX640…
Nikolaj Sørensen, President and CEO, said: "Once again, I am pleased with the USPTO recognising the inventiveness of our OX640 product and the AmorphOX technology. This is the eighth patent based on the technology, underscoring its uniqueness and value. In parallel, we continue to broaden the applications of AmorphOX by testing the technology with new substances, which is expected to lead to more patents. The extended exclusivity for OX640 build additional long-term value and improves the…
PR Newswire
17/04/2024
Temperature Controlled System Market to Reach $2.5 Billion Globally by 2032 at…
Download PDF Brochure: https://www.alliedmarketresearch.com/request-sample/A234567 Download PDF Brochure:https://www.alliedmarketresearch.com/request-sample/A234567 Prime Determinants of Growth The growing adoption of temperature controlled systems in various industries, such as logistics transportation, & pharmaceuticals, and the surging demand for integrity & quality of products are the factors expected to drive the growth of the global temperature controlled system...
PR Newswire
17/04/2024
Roche's subcutaneous OCREVUS one-year data demonstrates near-complete…
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeksThe twice-yearly, 10-minute SC injection has the potential to expand the usage of OCREVUS to treatment centres without IV infrastructure or with IV capacity limitationsU.S. FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024...
Nasdaq GlobeNewswire
17/04/2024
Essential Pharma Announces the Acquisition of Reminyl® (galantamine…
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral CapsulesReminyl® is an established CNS brand for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type The acquisition ensures continued access to this essential cholinesterase inhibitor for dementia patients in key marketsSignificant addition to Essential Pharma's portfolio of specialty central nervous system (CNS) medicines and further expands the company's...
Nasdaq GlobeNewswire
17/04/2024
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently…
Continuous Kesimpta ® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of the ALITHIOS open-label extension study 1 Similar efficacy outcomes were demonstrated in a separate analysis of continuous Kesimpta treatment for up to six years in the overall ALITHIOS study population 2 Switch from teriflunomide to Kesimpta resulted in significant...
Nasdaq GlobeNewswire
17/04/2024
Press Release: New 48-week frexalimab phase 2 data support potential for high…
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosisData support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis96% of participants receiving high-dose intravenous frexalimab had no new Gd+ T1 lesions and an annualized relapse rate of 0.04 after 48 weeksSanofi has initiated global phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary...
Nasdaq GlobeNewswire
17/04/2024
Idorsia publishes a Financial Status required for an upcoming bondholder meeting
Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company websiteBondholder meeting now planned for early May as the company continues to engage with bondholdersAllschwil, Switzerland – April 17, 2024Idorsia Ltd (SIX: IDIA) today announced that its Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting is available on the company website at...
Nasdaq GlobeNewswire
17/04/2024
Global Dental Lasers Market to Witness Upsurge in Growth at a CAGR of ~5% by…
Key Takeaways from the Dental Lasers Market Report Key Takeaways from the Dental Lasers Market Report To read more about the latest highlights related to the dental lasers market, get a snapshot of the key highlights entailed in theGlobal Dental Lasers Market Report Dental Lasers Overview Dental lasers have revolutionized the field of dentistry, offering a precise and minimally invasive alternative to traditional dental tools. These focused beams of light energy can be used...
PR Newswire
16/04/2024
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn)…
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of StelaraSELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and process...
Nasdaq GlobeNewswire
16/04/2024
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement…
Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1's potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% The operational...
Nasdaq GlobeNewswire
16/04/2024
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in…
ASPIRE-FTD Sites in the EU and U.S. to Use ClearPoint® Navigation Together With SmartFlow® Cannula for Intrathalamic Gene Therapy Administration /2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations. “FTD is an important cause of dementia in people under 65 and has a devastating impact on patients and families. The importance of accurately delivering this one-time gene therapy to the thalamus,...
Nasdaq GlobeNewswire
16/04/2024
Growth of 28% of 2024 first quarter revenue
Press release Ecully, April 16, 2024 – 8 p.m. First-quarter 2024 revenue of €3.1 millionGrowth of 28% compared with 2023 first quarter In thousands of euros 20242023Change 2023/2022Q1 revenue 3,0702,398+28%Unaudited consolidated data Spineway, a specialist in innovative implants for the treatment of severe spine disorders, recorded revenue of €3.1 million in the first quarter of 2024, an increase of 28% compared with the same period...
Nasdaq GlobeNewswire
16/04/2024
Altri Comunicati
